Review article · 2021 · Open access

Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials

Vinod Kumar Reddy Solipuram, Akhila Mohan, Roshniben Patel, Ruoning Ni

Autoimmunity Highlights, 12(1), 8 · Published 28 April 2021 · DOI 10.1186/s13317-021-00153-5

Open PDFView at the publisherCite this paper

In brief

“Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials” is a 2021 review article by Vinod Kumar Reddy Solipuram and 3 co-authors, published in Autoimmunity Highlights. OpenAlex counts 40 citations as of 19 November 2026, which puts it in the top 5% of works published in 2021 by citations. It is open access under a CC BY licence: the full text is free to read at Autoimmunity Highlights.

Citations
40
Most cited in
2023 (11)
Field-weighted impact
1.09
References
40
Authors
4

Abstract

BACKGROUND: Rheumatoid arthritis (RA) is a systemic autoimmune disease. The combination therapy of methotrexate (MTX) and Janus kinase inhibitor (JAKi) is commonly used. Patients with RA are at increased risk of malignancy, however, it remains unclear whether the combination therapy is associated with a higher risk. OBJECTIVE: To assess the malignancy risk among patients with RA receiving combination therapy of JAKi and MTX compared to MTX alone. METHODS: PubMed, Cochrane and Embase were thoroughly searched for randomized controlled trials (RCTs) in patients with RA receiving JAKi and MTX, from inception to July 2020. Primary endpoints were malignancy events, Non melanomatous skin cancer (NMSC) and malignancy excluding NMSC and secondary endpoints were serious adverse events (SAE), deaths. Risk ratio (RR) and 95% CI were calculated using the Mantel-Haenszel random-effect method. RESULTS: 659 publications were screened and 13 RCTs with a total of 6911 patients were included in the analysis. There was no statistically significant difference in malignancy [RR = 1.42; 95% CI (0.59, 3.41)], neither NMSC [RR = 1.44 (0.36, 5.76)] nor malignancies excluding NMSC [RR = 1.12 (0.40, 3.13)]. No statistically significant difference between the two groups for SAE [RR = 1.15 (0.90, 1.47)] and deaths [RR = 1.99 (0.75, 5.27)] was found. CONCLUSION: The adjunction of JAKi to MTX is not associated with an increased risk of malignancy when compared to MTX alone. There is no increased risk of SAE and deaths when compared to MTX alone in patients with RA.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Solipuram, V. K. R., Mohan, A., Patel, R., & Ni, R. (2021). Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Autoimmunity Highlights, 12(1), 8. https://doi.org/10.1186/s13317-021-00153-5

MLA 9

Solipuram, Vinod Kumar Reddy, et al. “Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.” Autoimmunity Highlights, vol. 12, no. 1, 2021, p. 8. https://doi.org/10.1186/s13317-021-00153-5.

Chicago

Solipuram, Vinod Kumar Reddy, Akhila Mohan, Roshniben Patel, and Ruoning Ni. 2021. “Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.” Autoimmunity Highlights 12 (1): 8. https://doi.org/10.1186/s13317-021-00153-5.

Harvard

Solipuram, V. K. R. et al. (2021) ‘Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials’, Autoimmunity Highlights, 12(1), p. 8. doi:10.1186/s13317-021-00153-5.

IEEE

V. K. R. Solipuram, A. Mohan, R. Patel, and R. Ni, “Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials,” Autoimmunity Highlights, vol. 12, no. 1, p. 8, 2021, doi: 10.1186/s13317-021-00153-5.

BibTeX

@article{solipuram2021effect,
  title     = {{Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials}},
  author    = {Solipuram, Vinod Kumar Reddy and Mohan, Akhila and Patel, Roshniben and Ni, Ruoning},
  journal   = {Autoimmunity Highlights},
  year      = {2021},
  volume    = {12},
  number    = {1},
  pages     = {8},
  doi       = {10.1186/s13317-021-00153-5},
  url       = {https://doi.org/10.1186/s13317-021-00153-5}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202133
202277
20231111
202499
202577
202633

Its field-weighted citation impact is 1.09: it has been cited 1.09 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • JAK inhibitors
  • methotrexate
  • combination therapy
  • cancer risk
  • non-melanoma skin cancer
  • serious adverse events
  • mortality

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Solipuram, V. K. R., Mohan, A., Patel, R., & Ni, R. (2021). Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Autoimmunity Highlights, 12(1), 8. https://doi.org/10.1186/s13317-021-00153-5

How many times has this paper been cited?

40 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Autoimmunity Highlights: sign in and open the PDF from this page.

Who wrote this paper?

Vinod Kumar Reddy Solipuram, Akhila Mohan, Roshniben Patel, Ruoning Ni.

What is the DOI of this paper?

10.1186/s13317-021-00153-5, permanently at https://doi.org/10.1186/s13317-021-00153-5. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.